Previous Article | Next Article 
Infection and Immunity, April 1999, p. 1633-1639, Vol. 67, No. 4
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Lipopolysaccharide Enhances the Production of
Vascular Endothelial Growth Factor by Human Pulp Cells in
Culture
K.
Matsushita,1
R.
Motani,1
T.
Sakuta,1
S.
Nagaoka,1
T.
Matsuyama,2
K.
Abeyama,3
I.
Maruyama,3
H.
Takada,4 and
M.
Torii1,*
Department of Operative Dentistry and
Endodontology, Kagoshima University Dental School, Kagoshima
890-8544,1 Department of Immunology and
Medical Zoology2 and Department of
Clinical Laboratory Medicine,3 Kagoshima
University Medical School, Kagoshima 890-8520, and Department
of Microbiology and Immunology, Tohoku University School of
Dentistry, Sendai 980-8575,4 Japan
Received 8 September 1998/Returned for modification 2 November
1998/Accepted 19 January 1999
 |
ABSTRACT |
We investigated whether vascular endothelial growth factor (VEGF)
production by human pulp cells (HPC) is regulated by lipopolysaccharide (LPS) in relation to the pathogenesis of pulpitis. Although HPC incubated with medium alone only marginally expressed VEGF mRNA and
produced a low level of VEGF as detected by enzyme-linked immunosorbent
assay, the VEGF mRNA expression and VEGF production were markedly
enhanced upon stimulation with LPS from Escherichia coli.
Prevotella intermedia LPS, phorbol 12-myristate 13-acetate, and
interleukin-6 also induced VEGF mRNA expression in HPC. A simian virus
40-infected HPC line also exhibited increased VEGF mRNA expression in
response to E. coli LPS, but lung and skin fibroblasts did
not. Fetal bovine serum (FBS) increased the sensitivity of HPC to LPS
in a dose-dependent manner. HPC did not express membrane CD14 on their
surfaces. However, the anti-CD14 monoclonal antibody MY4 inhibited VEGF
induction upon stimulation with LPS in HPC cultures in the presence of
10% FBS but not in the absence of FBS. LPS augmented the VEGF
production in HPC cultures in the presence of recombinant human soluble
CD14 (sCD14). To clarify the mechanisms of VEGF induction by LPS, we
examined the possible activation of the transcription factor AP-1 in
HPC stimulated with LPS, by a gel mobility shift assay. AP-1 activation
in HPC was clearly observed, whereas that in skin fibroblasts was not. The AP-1 inhibitor curcumin strongly inhibited LPS-induced VEGF production in HPC cultures. In addition, a protein synthesis inhibitor, cycloheximide, inhibited VEGF mRNA accumulation in response to LPS.
These results suggest that the enhanced production of VEGF in HPC
induced by LPS takes place via an sCD14-dependent pathway which
requires new protein synthesis and is mediated in part through AP-1 activation.
 |
INTRODUCTION |
An increase of vascular permeability
is involved in the acute phase of pulpitis as well as in acute
inflammation elsewhere in the body. However, in the case of pulpitis,
an excessive increase of vascular permeability easily results in edema
and necrosis, due to the specific anatomic characteristics of the pulp
tissue. The pulp tissue is enclosed in a rigid structure, and blood is supplied only through a small apical foramen. This foramen is used for
both blood supply and drainage. Furthermore, pulp tissue has no
collateral blood supply, so it is difficult to rapidly eliminate
filtrated fluid. Thus, pulp tissue, having such a limited system of
discharge, is susceptible to irreversible pulpitis.
Vasoactive inflammatory substances such as histamine, bradykinin,
serotonin, prostaglandins (PGs), and leukotrienes are known as
mediators that increase vascular permeability in pulp tissues (14). Vascular endothelial growth factor (VEGF) has also
recently attracted attention as a potent inducer of vascular
permeability and angiogenesis (7) and is involved in the
occurrence and progression of inflammation (12). VEGF is
thought of as a mitogenic factor specific for vascular endothelial
cells and acts in a paracrine manner. However, we recently demonstrated
that VEGF is also produced by human pulp cells (HPC) and that VEGF is
mitogenic not only on vascular endothelial cells but also on HPC, in an
autocrine manner (17).
Various components and products of bacteria which invade the dentin and
root canal are associated with the pathogenesis of pulpitis
(19). One of these components, lipopolysaccharide (LPS), is
a potent inducer of pulpitis (37). LPS induces many
inflammatory cytokines such as interleukin-1 (IL-1), IL-6, IL-8, and
tumor necrosis factor alpha (TNF-
) from human peripheral blood
mononuclear cells and gingival fibroblasts (16, 28). LPS
also induces increased arachidonic acid metabolism in the pulp; LPS was
shown to induce PGE2 and PGI2 production,
resulting in an increase of vascular permeability and neutrophil
infiltration (18). The pulp tissue thus treated with LPS
became acutely inflamed. VEGF could increase vascular permeability in
pulp tissue, and its activity was 50,000 times stronger than that of
histamine (25). However, it is not yet known whether HPC
produce VEGF in response to LPS stimulation or whether VEGF is
associated with the pathogenesis of pulpitis.
In this study, we first investigated whether LPS can induce VEGF in HPC
cultures, and we then attempted to clarify the mechanism of VEGF
induction by LPS. We also discuss the possible involvement of VEGF in
the pathogenesis of pulpitis.
 |
MATERIALS AND METHODS |
Specimens and probes.
LPS was prepared from Prevotella
intermedia ATCC 25611 by the hot phenol-water extraction method as
described previously (10). LPS extracted with hot
phenol-water from Escherichia coli O55:B5, phorbol
12-myristate 13-acetate (PMA), mithramycin A,
N-tosyl-L-phenylalanine chloromethyl ketone
(TPCK), and cycloheximide were purchased from Sigma Chemical Co. (St.
Louis, Mo.). Curcumin was purchased from Nacalai Tesque Inc. (Kyoto,
Japan). Recombinant human IL-6 was provided by Ajinomoto Co. (Yokohama,
Japan). The fluorescein isothiocyanate (FITC)-conjugated and
nonconjugated anti-CD14 monoclonal antibody (MAb) MY4, isotype-matched
control antibody mouse immunoglobulin G2b (MSIgG2b), FITC-conjugated
anti-CD11b and CD18 MAbs, and isotype-matched control antibody MSIgG1a
were purchased from Coulter Immunology (Hialeah, Fla.). A plasmid
containing VEGF cDNA (40) was kindly provided by M. Shibuya
(Faculty of Pharmaceutical Sciences, University of Tokyo, Tokyo,
Japan). A plasmid containing human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA (33) was a gift from I. Sakiyama (Chiba Cancer Center Research Institute and Hospital, Chiba, Japan). Each plasmid was digested with appropriate restriction enzymes to
obtain cDNA probes which were then used for the Northern blot analysis.
Cells.
Specimens of normal human pulp tissue were obtained
from first bicuspids extracted for orthodontologic reasons. The
explants were cultured in Eagle's modified minimum essential medium
(EMEM; Nissui Pharmaceutical Co., Tokyo, Japan), supplemented with 10% fetal bovine serum (FBS; GIBCO Life Technologies, Inc., Grand Island,
N.Y.) in plastic culture dishes with medium changes every 3 days for 10 to 15 days until confluent cell monolayers were formed. After three to
four subcultures, homogeneous, slim, spindle-shaped cells
(fibroblast-like cells) growing in characteristic swirls were obtained.
These primary cultures of HPC (HPC-5 and HPC-10) were used as confluent
monolayers at subculture passages 5 through 10. A simian virus 40 (SV40)-infected human pulp fibroblast cell line (LSC) was a gift from
A. Sato (Tokyo Medical and Dental University, Tokyo, Japan). Human lung
fibroblasts (MRC-5) and human skin fibroblasts (SF-MA) were obtained
from the Japanese Cancer Research Resources Bank and used in some
experiments as reference cells. HPC-5, HPC-10, and LSC had high
alkaline phosphatase activity similar to that of osteoblasts, but MRC-5
and SF-MA did not.
Preparation of recombinant soluble CD14.
A
ZAPII cDNA
library was prepared from synovial cells with a Timesaver cDNA
synthesis kit (Pharmacia, Uppsala, Sweden) and Gigapack II Plus
packaging extract (Stratagene, La Jolla, Calif.) and then amplified by
PCR with Extra DNA polymerase (Takara Shuzo, Tokyo, Japan) and T3 and
T7 primers. A mammalian cDNA library was established by ligating PCR
products to pcDL-SRa296 vector (29). Cos7 cells were
transfected with this library to obtain cDNA encoding the antigen
recognized by D10 antibody. The cells by which the antigen was
transiently expressed were screened by panning methods (23).
One of the positive clones which reacted with D10 antibody was
sequenced, and this cDNA was homologous with CD14 cDNA (26).
To delete eight C-terminal amino acids including a phosphatidyl-linkage
portion, the full CD14 cDNA was used to induce a point mutation, with a
site-directed mutagenesis kit (Takara) and an antisense primer
(5'-GGGCCCCTTGTTACAGCACCAGG-3'). Cos7 cells were then
transiently transfected with mutant CD14 and fed in CHO-S-SFMII, a
low-protein and serum-free medium (Gibco BRL). After a 7-day
incubation, the supernatant was collected and purified for recombinant
human soluble CD14 (rHusCD14) with D10 antibody-coated beads prepared
with a Hitrap N-hydroxysuccinimide-activated column
(Pharmacia). The purity of the rHusCD14 protein was confirmed in a
silver-stained gel after sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. The rHusCD14 concentration in the supernatants was
determined with a protein assay kit (Bio-Rad, Hercules, Calif.). Finally, 17.0 µg of purified materials per ml was obtained from 1.5 liters of the culture supernatants.
VEGF expression in HPC cultures.
HPC suspensions (5 × 105 cells/ml) were seeded in the wells of flat-bottom
microculture plates or 150-cm2 cell culture dishes (Nunc,
Roskilde, Denmark) in EMEM supplemented with 10% FBS. After incubation
for 4 days at 37°C in a 5% CO2 atmosphere, the cell
monolayers were washed with EMEM three times, and 100 µl or 30 ml of
EMEM without FBS was added, followed by culture for 24 h. The
monolayers were subsequently washed with EMEM three times, and then
test stimulants in EMEM with or without FBS were added. After a further
incubation for 1 to 72 h, the supernatant and sediment were
collected and used in the subsequent experiments. In competition
experiments, HPC were incubated for 24 h at 37°C in a 5%
CO2 atmosphere with E. coli LPS (1 µg/ml) in
EMEM supplemented with 10% FBS in the presence of various
concentrations of anti-CD14 MAb MY4. To examine the role of sCD14 in
VEGF production induced by LPS, we incubated HPC with E. coli LPS for 24 h at 37°C in a 5% CO2
atmosphere in FBS-free EMEM in the presence of various concentration of
rHusCD14. The culture supernatants were collected, and then the VEGF
concentration in each supernatant was measured. In some experiments,
various concentrations of curcumin, mithramycin A, and TPCK were added
simultaneously with LPS to HPC cultures. After incubation for 24 h, the culture supernatants were collected, and the VEGF concentrations
in the supernatants were measured.
Northern blot analysis.
The expression of VEGF mRNA by HPC
was examined by Northern blot analysis as described previously
(30). The total RNA from HPC was prepared by the acid
guanidinium-phenol-chloroform procedure (3). Total RNA (20 µg per lane) was resolved by electrophoresis through a 1.2% agarose
gel and transferred to a nylon membrane (Zeta-Probe; Bio-Rad
Laboratories, Richmond, Calif.) by electroblotting (31). The
membrane was hybridized with 32P-labeled cDNA probes
(6), then washed and exposed to an imaging plate for 1 h for analysis by a Bio-Imaging analyzer (BAS 1000 Mac; Fuji Photo Film
Co., Tokyo, Japan), and exposed to X-ray film (medical X-ray film;
Konica, Tokyo, Japan) at
80°C for several days for autoradiography.
The results are expressed as the relative mRNA accumulation, with GAPDH
mRNA as an internal standard.
Measurement of VEGF protein.
The concentrations of VEGF
protein in the culture supernatants were determined at the Tsukuba
Research Laboratories of Toagosei Co. (Ibaragi, Japan) by enzyme-linked
immunosorbent assay (ELISA).
Flow cytometry analysis.
The analysis of cell surface CD14,
CD11b, and CD18 expression was conducted by a FACScan (Becton
Dickinson, Mountain View, Calif.). HPC and THP-1 cells were grown in
monolayers in cell culture dishes in Dulbecco's modified minimum
essential medium (DMEM) supplemented with 10% FBS. The cells were
washed once with serum-free DMEM and detached from the dishes with
0.02% EDTA for 5 min. The detached cells were immediately placed in
DMEM supplemented with 10% FBS. The detached HPC and THP-1 cells were
washed twice with phosphate-buffered saline. The cells were incubated
with the FITC-labeled anti-CD14, CD11b, and CD18 MAbs for 30 min at 4°C. As a negative control, the cells were also incubated with the
isotype-matched control antibody MSIgG1a or MSIgG2b.
Analyses of DNA-transcription factor binding.
Nuclear
extracts were prepared as described by Jimi et al. (13) and
were used for the following experiments.
(i) Gel mobility shift assay.
This assay was conducted as
described previously (13). Briefly, DNA binding was assayed
with a synthetic oligonucleotide probe for wild-type AP-1
(5'-TTGATGACTCA-3'). Probes were labeled by T4
polynucleotide kinase with [
-32P]ATP. Nuclear protein
extracts (10 µg) were incubated for 30 min with the labeled probe at
30°C, then loaded onto a 5% polyacrylamide gel, and electrophoresed
at 175 V for 70 min. After electrophoresis, the gels were dried and
autoradiographed by exposure to X-ray film at
80°C for several days.
(ii) Fluorescence polarization analysis.
To test the
activations of NF-
B and SP-1, a fluorescence polarization analysis
of DNA-protein binding was performed by using a Beacon 2000 fluorescence polarization system (PanVera Co., Madison, Wis.) according
to the manufacturer's instructions. Briefly, DNA FITC-labeled
oligonucleotide probes for wild-type SP-1 (5'-GATCGGGGCGGGGC-3') and NF-
B (5'-AGCTTGGGGACTTTCCGAG-3') were
synthesized at the laboratories of Takara Shuzo. The three
double-stranded FITC-labeled oligonucleotides were prepared by
annealing in 1 M NaCl-10 mM potassium phosphate-0.1 mM EDTA at 95°C
for 10 min. The various concentrations of the nuclear protein extracts
(10 µl) were added to 190 µl of binding buffer (20 mM Tris-HCl [pH
7.6], 100 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol) containing an
oligonucleotide (1 nM) in 6- by 50-mm borosilicate test tubes (PanVera
Co.). The tubes were incubated at 10°C for 1 h, and then the
fluorescence polarization values were determined. The data reported are
the values which were deducted from the value in the control tube (binding buffer supplemented with FITC-labeled oligonucleotide alone).
Statistical analysis.
Most assays were carried out in
triplicate. The significance of differences between the results of each
test and the respective control was determined by one-way analysis of
variance (ANOVA) and Scheffé's F test.
 |
RESULTS |
VEGF induction by LPS in HPC cultures.
As shown in Fig.
1, E. coli LPS induced VEGF
mRNA in HPC cultures, and the strongest expression of VEGF mRNA was
observed when HPC were stimulated with 0.1 µg of E. coli
LPS per ml. VEGF mRNA was marginally expressed by HPC even when the HPC
were cultured with EMEM alone. In accord with the gene expression, VEGF
was also detected in the supernatant of HPC cultures by ELISA, and the
level was increased in correlation with the addition of LPS (Fig.
2). VEGF mRNA expression by HPC began to
increase after 1 h of stimulation with E. coli LPS and
reached a maximum level after 6 h of stimulation (Fig.
3A). The induction of VEGF by E. coli LPS was clearly observed from 12 h of cultivation onward (Fig. 3B).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Induction of VEGF mRNA by E. coli LPS in HPC.
Confluent cultures of HPC-5 were washed and incubated in FBS-free EMEM
for 24 h. The cells were washed, fed with EMEM with 1% FBS, and
incubated with various concentrations of E. coli LPS for
6 h. Total RNA was extracted and analyzed by Northern blotting. To
control for variation in gel loading, the GAPDH mRNA expression in each
lane was also analyzed, and blots were quantified by means of a
Bio-Imaging analyzer (BAS 1000 Mac). The results are expressed as the
relative mRNA accumulation compared with GAPDH mRNA as an initial
standard.
|
|

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 2.
Enhanced production of VEGF by HPC stimulated with
E. coli LPS. Confluent cultures of HPC-5 were washed and
incubated in FBS-free EMEM for 24 h. The cells were washed, fed
with EMEM with 1% FBS, and incubated with various concentrations of
E. coli LPS for 24 h. Triplicate culture supernatants
were pooled, and their VEGF concentrations were determined by ELISA.
The data are expressed as means ± standard deviations of
triplicate assays. The absorbance level was significantly different
from that of the control (medium alone) by ANOVA and Scheffé's
F test (**, P < 0.01).
|
|

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 3.
Kinetics of LPS effect on VEGF induction on HPC.
Confluent cultures of HPC-5 were washed and incubated in FBS-free EMEM
for 24 h. The cells were washed, fed with EMEM with 1% FBS, and
incubated with 10 µg of E. coli LPS per ml for 0 to
48 h. Total RNA was extracted and analyzed by Northern blotting.
To control for variation in gel loading, the GAPDH mRNA expression in
each lane also was analyzed. (A) Northern blotting was performed as
described in the legend to Fig. 1. (B) ELISA was performed as described
in the legend to Fig. 2.
|
|
Next, we examined whether other stimulants enhance the expression of
VEGF mRNA in HPC cultures. As shown in Fig.
4, LPS from P. intermedia,
which is a putative pathogen of pulpitis, strongly induced VEGF mRNA,
similarly to E. coli LPS. PMA and IL-6 also induced VEGF
mRNA in HPC cultures.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 4.
Enhancing effects of PMA, IL-6, and E. coli
and P. intermedia LPS on VEGF mRNA expression by HPC.
Confluent cultures of HPC-5 were washed and incubated in FBS-free EMEM
for 24 h. The cells were washed, fed with EMEM with 1% FBS, and
incubated with PMA (10 µg/ml), IL-6 (50 U/ml), E. coli LPS
(10 µg/ml), or P. intermedia (P. i.) LPS (10 µg/ml) for 6 h. The other procedures are described in the legend
to Fig. 1.
|
|
To examine whether other fibroblasts from pulp and other organs also
express VEGF upon LPS stimulation, we examined the expression
of VEGF
mRNA in another primary culture of HPC (HPC-10), an SV40-infected
cell
line of HPC (LSC), skin fibroblasts (SF-MA), and lung fibroblasts
(MRC-5). We found that HPC-10 and LSC as well as HPC-5 expressed
VEGF
mRNA upon stimulation with
E. coli LPS (10 µg/ml), but
SF-MA
and MRC-5 did not (Fig.
5).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 5.
VEGF mRNA induction in various fibroblast cell lines by
E. coli LPS. Confluent primary cultures of HPC (HPC-5 and
HPC-10), SV40-infected human pulp cells (LSC), skin fibroblasts
(SF-MA), and lung fibroblasts (MRC-5) were washed and incubated in
FCS-free EMEM for 24 h. The cells were washed, fed with EMEM with
1% FCS, and incubated with medium alone or 10 µg of E. coli LPS per ml for 4 h. Total RNA was extracted and analyzed
by Northern blotting. To control for variation in gel loading, the
GAPDH mRNA expression in each lane was also analyzed.
|
|
Uchida et al. (
34) showed that FBS induces VEGF in
glomerular endothelial cell cultures. To examine the effect of FBS on
VEGF production by HPC, HPC-5 were stimulated with
E. coli
LPS
in EMEM containing various concentrations of FBS, and then the
levels of VEGF mRNA in these cultures were measured. Although
VEGF mRNA
was expressed even in HPC cultured with EMEM alone for
6 h, the
extent of expression was slightly enhanced by the addition
of FBS (Fig.
6). The levels of VEGF mRNA induced by
E. coli LPS
were significantly enhanced by the addition of
FBS.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 6.
Effect of FBS concentration on VEGF production by HPC.
Confluent cultures of HPC-5 were washed and incubated in FBS-free EMEM
for 24 h. The cells were washed and then fed with EMEM
supplemented with various concentrations of FBS (0, 0.1, 1, and 10%
[vol/vol]). One microgram of E. coli LPS per milliliter
was then added, followed by incubation for 4 h. Other procedures
are described in the legend to Fig. 1.
|
|
Role of CD14 in the LPS-augmented VEGF expression in HPC
cultures.
LPS receptors such as CD14 and
2
integrins (CD11b/CD18 and CD11c/CD18) are crucial for monocytes and
macrophages to respond to LPS (11, 38). We investigated
whether CD14, CD11b, and CD18 were expressed on the surfaces of HPC and
the skin fibroblasts SF-MA. HPC and SF-MA expressed CD18 on the cell
surface but not CD11b and CD14 (data not shown).
Hayashi et al. (
9) reported that the induction of
intercellular adhesion molecule 1 by LPS on human gingival fibroblasts
is mediated by serum-derived sCD14. To clarify the participation
of
sCD14 in FBS in the enhanced production of VEGF by HPC stimulated
with
LPS, we added neutralizing anti-CD14 MAb MY4 to HPC cultures
stimulated
with LPS. As shown in Fig.
7, MY4 (50 µg/ml) strongly
inhibited the VEGF production induced by
E. coli LPS in HPC cultures.
Furthermore, we also examined the effect
of rHusCD14 on LPS-induced
VEGF production in HPC cultures. With the
addition of 5 or 50
ng of rHusCD14 per ml, the VEGF production induced
by
E. coli LPS was significantly enhanced in HPC cultures in
the absence
of FBS (Fig.
8). The rHusCD14
alone did not influence the VEGF
production by HPC, and the augmenting
effect of rHusCD14 was not
observed in SF-MA cultures stimulated with
E. coli LPS (data not
shown).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 7.
Effect of anti-CD14 MAb on LPS-elicited VEGF production
by HPC. HPC-5 (5 × 105 cells/ml) were incubated with
1 µg of E. coli LPS per ml in EMEM supplemented with 0, 1, or 10% FBS. Various amounts of anti-CD14 MAb were added at 15 min
before LPS exposure. After incubation for 24 h, triplicate culture
supernatants were pooled, and their VEGF concentrations were determined
by ELISA. The data are the means ± standard deviations of
triplicate assays.
|
|

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 8.
Effect of sCD14 on LPS-elicited VEGF production by HPC.
HPC-5 (5 × 105 cells/ml) were incubated with various
concentrations of rHusCD14 in EMEM without FCS for 15 min, and E. coli LPS (1 µg/ml) was added (closed bars) or not added (hatched
bar). After incubation for 24 h, triplicate culture supernatants
were pooled, and their VEGF concentrations were determined by ELISA.
The data are the means ± standard deviations of triplicate
assays. The absorbance level was significantly different from that of
the control (medium alone) by one-way ANOVA and Scheffé's
F test (**, P < 0.01).
|
|
Role of nuclear factor AP-1 in the LPS-augmented VEGF expression in
HPC cultures.
To clarify the signaling pathway of LPS for VEGF
induction in HPC, we examined whether LPS modulates the activities of
the nuclear factor AP-1 by a gel mobility shift assay. As shown in Fig.
9, HPC cultured in EMEM in the presence
of 10% FBS for 4 h showed AP-1 activation, and the activation
level was significantly enhanced by the addition of 1 µg of E. coli LPS per ml to the culture. No enhancement of AP-1 activation
by LPS was observed in SF-MA cultures, although marginal AP-1
activation was observed in SF-MA cultured in EMEM in the presence of
10% FBS. We also examined the activation of two other nuclear factors,
NF-
B and SP-1, in HPC and SF-MA by a fluorescence polarization
analysis of DNA-protein binding. NF-
B and SP-1 were also activated
in both HPC and the reference SF-MA upon stimulation with E. coli LPS, and their levels of activation in SF-MA were greater
than those in HPC (data not shown). To clarify which transcription factors were predominantly associated with the enhanced production of
VEGF by HPC stimulated with LPS, we examined the effects of inhibitors
of AP-1, SP-1, and NF-
B. VEGF induction by E. coli LPS in
HPC cultures was definitely inhibited by the AP-1 inhibitor curcumin in
a dose-dependent manner, whereas the SP-1 inhibitor mithramycin A and
the NF-
B inhibitor TPCK were inactive in this respect (data not
shown). To ascertain whether newly synthesized proteins are necessary
for the VEGF mRNA expression induced by LPS, the protein synthesis
inhibitor cycloheximide was added to HPC cultures. Cycloheximide at 25 µg/ml was sufficient to inhibit VEGF mRNA accumulation in response to
E. coli LPS or P. intermedia LPS (Fig.
10). These results indicate that the
expression of VEGF enhanced by LPS required new protein synthesis and
appeared to be mediated in part through the transcription factor AP-1.

View larger version (63K):
[in this window]
[in a new window]
|
FIG. 9.
Analysis of AP-1 activation by LPS in HPC by a gel
mobility shift assay. Confluent cultures of HPC-5 and SF-MA were
preincubated in medium alone for 18 h and then further incubated
in medium alone or with E. coli LPS (1 µg/ml) for 4 h. Nuclear extracts were prepared and gel mobility shift assays were
carried out as described in the text.
|
|

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 10.
Effect of cycloheximide (CHX) on LPS-elicited VEGF mRNA
expression by HPC. Confluent cultures of HPC-5 were incubated with or
without the following materials in various concentrations in EMEM
supplemented with 10% FBS: E. coli LPS (1 µg/ml),
P. intermedia (P. i.) LPS (1 µg/ml), and
cycloheximide (10 µg/ml) for 4 h. Other procedures are described
in the legend to Fig. 1.
|
|
 |
DISCUSSION |
In this study, we observed that HPC produced more VEGF in response
to E. coli LPS, through an sCD14-dependent pathway. The LPS-induced VEGF expression was in part mediated by AP-1 activation. Several potential binding sites for the transcription factors AP-1,
AP-2, and SP-1 are localized in the VEGF promoter, and it is thought
that these transcription factors are associated with VEGF expression
(8, 24). Ryuto et al. (21) reported that basic
fibroblast growth factor and TNF-
strongly enhance VEGF mRNA levels
in a glioma cell line, and they suggested that this phenomenon is
mediated through the transcription factor SP-1. Since HPC also express
VEGF mRNA in response to TNF-
(17), the TNF-
-augmented
VEGF mRNA expression in HPC cultures may be mediated through SP-1
activation. Another possibility is that LPS induces VEGF mRNA in HPC by
a mechanism different from that for TNF-
; TNF-
and LPS induce
VEGF gene expression in HPC in part through SP-1 and AP-1,
respectively. Further studies are required to reach a final conclusion
on this issue. Cycloheximide inhibited the LPS-induced VEGF mRNA
expression (Fig. 10). A sufficient supply of c-Fos and c-Jun, which
produce AP-1, is essential for the activation of AP-1 (2).
LPS induced the expression of c-fos and c-jun
genes in human monocytes (5). The VEGF induction by LPS in
HPC may therefore be mediated by an ongoing synthesis of c-Fos and
c-Jun protein. We recently showed that a human monocytic cell line,
THP-1, exhibited increased VEGF production in response to E. coli LPS, and the effect of LPS depended on SP-1 activation (22), suggesting that the intracellular signaling of LPS for VEGF production is different among cell types.
Several studies of macrophages have shown that a membrane
glycosylphosphatidylinositol-anchored CD14 molecule (mCD14) mediates LPS-induced cell activation (35, 39). A soluble form of CD14 (sCD14) lacking the glycosylphosphatidylinositol anchor is also present
in serum (1), and sCD14 participates in the LPS-induced activation of endothelial and epithelial cells that normally do not
express mCD14 (20). Hayashi et al. (9) indicated
that although human gingival fibroblasts (HGF) expressed neither CD14 mRNA nor mCD14 on the cell surface, HGF were activated with LPS in a
manner dependent on serum-derived sCD14 molecules. In contrast, Watanabe et al. (36) reported mCD14 expression by HGF.
Sugawara et al. (27) recently showed heterogeneity of HGF in
regard to mCD14 expression. In our study, a flow cytometric analysis
showed that mCD14 expression was not present in HPC (data not shown). LPS scarcely enhanced the VEGF mRNA expression in HPC when the HPC were
cultured in EMEM without FBS. The presence of FBS allowed HPC, in a
dose-dependent manner, to express VEGF mRNA in response to LPS. In
fact, the VEGF induction by LPS was inhibited by anti-CD14 MAb MY4, and
rHusCD14 reconstituted the VEGF production in response to LPS in HPC
cultured in serum-free medium. These findings strongly suggest that HPC
respond to LPS in an sCD14-dependent manner. LPS binding protein (LBP)
is present in normal sera from many species, including humans and cows,
and was suggested to bind LPS to form a complex which strongly binds
CD14 (32). Therefore, LPS associates with LBP in FBS, and
this complex in turn binds efficiently to sCD14. This LPS-LBP-sCD14
complex might stimulate HPC and strongly induce VEGF.
Besides HPC, reference fibroblasts SF-MA, which originate from skin,
also responded to E. coli LPS; SF-MA stimulated with E. coli LPS also showed the activation of NF-
B, AP-1, and
SP-1 (data not shown). However, VEGF mRNA was not induced in SF-MA stimulated with LPS (Fig. 5). These findings may be explained as
follows: although LPS stimulated SF-MA to activate AP-1, the level of
activation was not enough to modulate the VEGF gene expression. In
fact, in SF-MA transfected with NF-
B and SP-1 binding-site-deletion (AP-1 binding-site-retained) human immunodeficiency virus long terminal
repeat luciferase (luc) gene, luc activity was not enhanced upon
stimulation with E. coli LPS, whereas it was enhanced in the
corresponding HPC transfectant (15). In addition, HPC and SF-MA which were transfected with NF-
B binding-site-deletion (AP-1
and SP-1 binding-site-retained) HIV long terminal repeat luc gene did
not show enhanced luc activity upon stimulation with LPS
(15). Since SP-1 was strongly activated in LPS-stimulated SF-MA compared with that in LPS-stimulated HPC in the present study,
SP-1 may suppress the VEGF production by fibroblasts stimulated with LPS.
It is reasonable that HPC strongly produce VEGF in response to various
stimulants containing LPS to compensate for the limited system of blood
circulation in pulp tissue. Since the pulp is enclosed by hard tissue
and is supplied with blood only through a small apical foramen,
inflammation or injury occurring in pulp tissue followed by poor blood
flow might immediately result in necrosis. HPC may therefore have a
specific capacity for VEGF production to counteract this vulnerability.
VEGF induces not only increased vascular permeability but also the
chemotaxis of monocytes/macrophages (4). An upregulated
production of VEGF in dental pulp may therefore enhance vascular
permeability and the accumulation of inflammatory cells and increase
the blood pressure, which results in the irreversible inflammation of
dental pulp. However, VEGF also promotes the chemotaxis, proliferation, and differentiation of HPC (15, 16). In the recovery phase of inflamed pulp tissue, a sufficient supply of blood and angiogenesis are required. VEGF thus might also be useful for the cure of inflamed pulp tissue; VEGF promotes angiogenesis in the inflammatory sites of
dental pulp and may induce the proliferation and differentiation of HPC
and therefore might contribute to the repair of damaged pulp tissue and
dentin. If the localization and action of VEGF in pulp tissue in vivo
can be ascertained, the role of VEGF in pulp may become clear.
 |
ACKNOWLEDGMENTS |
We are indebted to M. Suwa, T. Oyama, T. Tajima, and K. Tomita
for experimental assistance. We thank D. Mrozek (Medical English Service, Kyoto, Japan) for reviewing the paper.
This work was supported in part by Grants-in-Aid for Scientific
Research from the Ministry of Education, Science, Sports and Culture of
Japan (no. 08771712).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Operative Dentistry and Endodontology, Kagoshima University Dental
School, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan. Phone and fax: 81-99-275-6190. E-mail:
toriim{at}dentb.hal.kagoshima-u.ac.jp.
Editor:
J. R. McGhee
 |
REFERENCES |
| 1.
|
Bazil, V.,
M. Baudys,
I. Hilgert,
I. Stefanova,
M. G. Low,
J. Zbrozek, and V. Horejsi.
1989.
Structural relationship between the soluble and membrane-bound forms of human monocyte surface glycoprotein CD14.
Mol. Immunol.
26:657-662[Medline].
|
| 2.
|
Chen, Y.,
A. Takeshita,
K. Ozaki,
S. Kitano, and S. Hanazawa.
1996.
Transcriptional regulation by transforming growth factor beta of the expression of retinoic acid and retinoid X receptor genes in osteoblastic cells is mediated through AP-1.
J. Biol. Chem.
271:31602-31606[Abstract/Free Full Text].
|
| 3.
|
Chomczynski, P., and N. Sacchi.
1987.
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.
Anal. Biochem.
162:156-159[Medline].
|
| 4.
|
Clauss, M.,
H. Weich,
G. Breier,
U. Knies,
W. Rockl,
J. Waltenberger, and W. Risau.
1996.
The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis.
J. Biol. Chem.
271:17629-17634[Abstract/Free Full Text].
|
| 5.
|
Delpedro, A. D.,
M. J. Barjavel,
Z. Mamdouh, and O. Bakouche.
1998.
Activation of human monocytes by LPS and DHEA.
J. Interferon Cytokine Res.
18:125-135[Medline].
|
| 6.
|
Feinberg, R. F.,
L. H. Sun,
C. P. Ordahl, and F. R. Frankel.
1983.
Identification of glucocorticoid-induced genes in rat hepatoma cells by isolation of cloned cDNA sequences.
Proc. Natl. Acad. Sci. USA
80:5042-5046[Abstract/Free Full Text].
|
| 7.
|
Ferrara, N.
1995.
The role of vascular endothelial growth factor in pathological angiogenesis.
Breast Cancer Res. Treat.
36:127-137[Medline].
|
| 8.
|
Finkenzeller, G.,
A. Technau, and D. Marme.
1995.
Hypoxia-induced transcription of the vascular endothelial growth factor gene is independent of functional AP-1 transcription factor.
Biochem. Biophys. Res. Commun.
208:432-439[Medline].
|
| 9.
|
Hayashi, J.,
T. Masaka,
I. Saito, and I. Ishikawa.
1996.
Soluble CD14 mediates lipopolysaccharide-induced intracellular adhesion molecule 1 expression in cultured human gingival fibroblasts.
Infect. Immun.
64:4946-4951[Abstract].
|
| 10.
|
Iki, K.,
K. Kawahara,
S. Sawamura,
R. Arakaki,
T. Sakuta,
A. Sugiyama,
H. Tamura,
T. Sueda,
S. Hamada, and H. Takada.
1997.
A novel component different from endotoxin extracted from Prevotella intermedia ATCC 25611 activates lymphoid cells from C3H/HeJ mice and gingival fibroblasts from humans.
Infect. Immun.
65:4531-4538[Abstract].
|
| 11.
|
Ingalls, R. R., and D. T. Golenbock.
1995.
CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide.
J. Exp. Med.
181:1473-1479[Abstract/Free Full Text].
|
| 12.
|
Ito, A.,
S. Hirota,
H. Mizuno,
Y. Kawasaki,
T. Takemura,
T. Nishiura,
Y. Kanakura,
Y. Katayama,
S. Nomura, and Y. Kitamura.
1995.
Expression of vascular permeability factor (VPF/VEGF) messenger RNA by plasma cells: possible involvement in the development of edema in chronic inflammation.
Pathol. Int.
45:715-720[Medline].
|
| 13.
|
Jimi, E.,
T. Ikebe,
N. Takahashi,
M. Hirata,
T. Suda, and T. Koga.
1996.
Interleukin-1 activates an NF- B-like factor in osteoclast-like cells.
J. Biol. Chem.
271:4605-4608[Abstract/Free Full Text].
|
| 14.
|
Kim, S.,
M. Liu,
S. Simchon, and J. E. Dorscher-Kim.
1992.
Effects of selected inflammatory mediators on blood flow and vascular permeability in the dental pulp.
Proc. Finn. Dent. Soc.
88:387-392.
|
| 15.
| Matsushita, K., and R. Motani. Unpublished data.
|
| 16.
|
Matsushita, K.,
S. Nagaoka,
R. Arakaki,
Y. Kawabata,
K. Iki,
M. Kawagoe, and H. Takada.
1994.
Immunobiological activities of a 55-kilodalton cell surface protein of Prevotella intermedia ATCC 25611.
Infect. Immun.
62:2459-2469[Abstract/Free Full Text].
|
| 17.
|
Motani, R.,
K. Matsushita,
T. Sakuta,
M. Suwa,
T. Oyama,
Y. Sakoda,
M. Torii, and S. Nagaoka.
1997.
Properties of vascular endothelial growth factor on human pulpal cells.
Jpn. J. Conserv. Dent.
40:1121-1130.
|
| 18.
|
Okiji, T.,
I. Morita,
I. Sunada, and S. Murota.
1989.
Involvement of arachidonic acid metabolites in increases in vascular permeability in experimental dental pulpal inflammation in the rat.
Arch. Oral Biol.
34:523-528[Medline].
|
| 19.
|
Pekovic, D. D., and E. D. Fillery.
1984.
Identification of bacteria in immunopathologic mechanisms of human dental pulp.
Oral Surg. Oral Med. Oral Pathol.
57:652-661[Medline].
|
| 20.
|
Read, M. A.,
S. R. Cordle,
R. A. Veach,
C. D. Carlisle, and J. Hawiger.
1993.
Cell-free pool of CD14 mediates activation of transcription factor NF- B by lipopolysaccharide in human endothelial cells.
Proc. Natl. Acad. Sci. USA
90:9887-9891[Abstract/Free Full Text].
|
| 21.
|
Ryuto, M.,
M. Ono,
H. Izumi,
S. Yoshida,
H. A. Weich,
K. Kohno, and M. Kuwano.
1996.
Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1.
J. Biol. Chem.
271:28220-28228[Abstract/Free Full Text].
|
| 22.
| Sakuta, T., K. Matsushita, N. Yamaguchi, T. Koga, K. Abeyama, I. Maruyama, H. Takada, and M. Torii. Submitted for
publication.
|
| 23.
|
Seed, B., and A. Aruffo.
1987.
Molecular cloning of CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure.
Proc. Natl. Acad. Sci. USA
84:3365-3369[Abstract/Free Full Text].
|
| 24.
|
Shima, D. T.,
M. Kuroki,
U. Deutsch,
Y. S. Ng,
A. P. Adamis, and P. A. D'Amore.
1996.
The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences.
J. Biol. Chem.
271:3877-3883[Abstract/Free Full Text].
|
| 25.
|
Shulman, K.,
S. Rosen,
K. Tognazzi,
E. J. Manseau, and L. F. Brown.
1996.
Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases.
J. Am. Soc. Nephrol.
7:661-666[Abstract].
|
| 26.
|
Simmons, D. L.,
S. Tan,
D. G. Tenen,
A. Nicholson Weller, and B. Seed.
1989.
Monocyte antigen CD14 is a phospholipid anchored membrane protein.
Blood
73:284-289[Abstract/Free Full Text].
|
| 27.
|
Sugawara, S.,
A. Sugiyama,
E. Nemoto,
H. Rikiishi, and H. Takada.
1998.
Heterogeneous expression and release of CD14 by human gingival fibroblasts: characterization and CD14-mediated interleukin-8 secretion in response to lipopolysaccharide.
Infect. Immun.
66:3043-3049[Abstract/Free Full Text].
|
| 28.
|
Takada, H.,
J. Mihara,
I. Morisaki, and S. Hamada.
1991.
Induction of interleukin-1 and -6 in human gingival fibroblast cultures stimulated with Bacteroides lipopolysaccharides.
Infect. Immun.
59:295-301[Abstract/Free Full Text].
|
| 29.
|
Takebe, Y.,
M. Seiki,
J. Fujisawa,
P. Hoy,
K. Yokota,
K. Arai,
Y. Yoshida, and N. Arai.
1988.
SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat.
Mol. Cell. Biol.
8:466-472[Abstract/Free Full Text].
|
| 30.
|
Tamura, M.,
M. Tokuda,
S. Nagaoka, and H. Takada.
1992.
Lipopolysaccharides of Bacteroides intermedius (Prevotella intermedia) and Bacteroides (porphyromonas) gingivalis induce interleukin-8 gene expression in human gingival fibroblast cultures.
Infect. Immun.
60:4932-4937[Abstract/Free Full Text].
|
| 31.
|
Thomas, P. S.
1980.
Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.
Proc. Natl. Acad. Sci. USA
77:5201-5205[Abstract/Free Full Text].
|
| 32.
|
Tobias, P. S.,
K. Soldau,
L. Kline,
J. D. Lee,
K. Kato,
T. P. Martin, and R. J. Ulevitch.
1993.
Cross-linking of lipopolysaccharide (LPS) to CD14 on THP-1 cells mediated by LPS-binding protein.
J. Immunol.
150:3011-3021[Abstract].
|
| 33.
|
Tokunaga, K.,
Y. Nakamura,
K. Sakata,
K. Fujimori,
M. Ohkubo,
K. Sawada, and S. Sakiyama.
1987.
Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers.
Cancer Res.
47:5616-5619[Abstract/Free Full Text].
|
| 34.
|
Uchida, K.,
S. Uchida,
K. Nitta,
W. Yumura,
F. Marumo, and H. Nihei.
1994.
Glomerular endothelial cells in culture express and secrete vascular endothelial growth factor.
Am. J. Physiol.
266:81-88.
|
| 35.
|
Ulevitch, R. J., and P. S. Tobias.
1995.
Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin.
Annu. Rev. Immunol.
13:437-457[Medline].
|
| 36.
|
Watanabe, A.,
A. Takeshita,
S. Kitano, and S. Hanazawa.
1996.
CD14-mediated signal pathway of Porphyromonas gingivalis lipopolysaccharide in human gingival fibroblasts.
Infect. Immun.
64:4488-4494[Abstract].
|
| 37.
|
Warfvinge, J.,
G. Dahlen, and G. Bergenholtz.
1985.
Dental pulp response to bacterial cell wall material.
J. Dent. Res.
64:1046-1050[Abstract/Free Full Text].
|
| 38.
|
Wright, S. D., and M. T. Jong.
1986.
Adhesion-promoting receptors on human macrophages recognize Escherichia coli by binding to lipopolysaccharide.
J. Exp. Med.
164:1876-1888[Abstract/Free Full Text].
|
| 39.
|
Wright, S. D.,
R. A. Ramos,
P. S. Tobias,
R. J. Ulevitch, and J. C. Mathison.
1990.
CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.
Science
249:1431-1433[Abstract/Free Full Text].
|
| 40.
|
Yamane, A.,
L. Seetharam,
S. Yamaguchi,
N. Gotoh,
T. Takahashi,
G. Neufeld, and M. Shibuya.
1994.
A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1).
Oncogene
9:2683-2690[Medline].
|
Infection and Immunity, April 1999, p. 1633-1639, Vol. 67, No. 4
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Staquet, M.-J., Durand, S.H., Colomb, E., Romeas, A., Vincent, C., Bleicher, F., Lebecque, S., Farges, J.-C.
(2008). Different Roles of Odontoblasts and Fibroblasts in Immunity. JDR
87: 256-261
[Abstract]
[Full Text]
-
Telles, P.D.S., Hanks, C.T., Machado, M.A.A.M., Nor, J.E.
(2003). Lipoteichoic Acid Up-regulates VEGF Expression in Macrophages and Pulp Cells. JDR
82: 466-470
[Abstract]
[Full Text]
-
Pollmann, C., Huang, X., Mall, J., Bech-Otschir, D., Naumann, M., Dubiel, W.
(2001). The Constitutive Photomorphogenesis 9 Signalosome Directs Vascular Endothelial Growth Factor Production in Tumor Cells. Cancer Res.
61: 8416-8421
[Abstract]
[Full Text]
-
Shi, Q., Le, X., Abbruzzese, J. L., Peng, Z., Qian, C.-N., Tang, H., Xiong, Q., Wang, B., Li, X.-C., Xie, K.
(2001). Constitutive Sp1 Activity Is Essential for Differential Constitutive Expression of Vascular Endothelial Growth Factor in Human Pancreatic Adenocarcinoma. Cancer Res.
61: 4143-4154
[Abstract]
[Full Text]
-
SAKUTA, T., MATSUSHITA, K., YAMAGUCHI, N., OYAMA, T., MOTANI, R., KOGA, T., NAGAOKA, S., ABEYAMA, K., MARUYAMA, I., TAKADA, H., TORII, M.
(2001). Enhanced production of vascular endothelial growth factor by human monocytic cells stimulated with endotoxin through transcription factor SP-1. J Med Microbiol
50: 233-237
[Abstract]
[Full Text]
-
Matsushita, K., Motani, R., Sakutal, T., Yamaguchi, N., Koga, T., Matsuo, K., Nagaoka, S., Abeyama, K., Maruyama, I., Torii, M.
(2000). The Role of Vascular Endothelial Growth Factor in Human Dental Pulp Cells: Induction of Chemotaxis, Proliferation, and Differentiation and Activation of the AP-1-dependent Signaling Pathway. JDR
79: 1596-1603
[Abstract]
-
Cario, E., Rosenberg, I. M., Brandwein, S. L., Beck, P. L., Reinecker, H.-C., Podolsky, D. K.
(2000). Lipopolysaccharide Activates Distinct Signaling Pathways in Intestinal Epithelial Cell Lines Expressing Toll-Like Receptors. J. Immunol.
164: 966-972
[Abstract]
[Full Text]